ResMed (RMD) CEO on GLP-1 Drugs: "This is a Really Exciting Moment for Global Healthcare System"

@ResMedAmericas CEO Michael Farrell joins Oliver Renick to talk about the rise of GLP-1 drugs and its impact on the CPAP Therapy. He also discusses A.I.'s use in sleep and respiratory care, and ResMed's latest earnings.

Market On Close

08 Aug 2024

SHARE